Summit Therapeutics PLC (SMMT)
| Market Cap | 478.14M |
| Revenue (ttm) | 615,000 |
| Net Income (ttm) | -73.05M |
| Shares Out | 90.65M |
| EPS (ttm) | -0.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 121,244 |
| Open | 5.09 |
| Previous Close | 5.06 |
| Day's Range | 4.90 - 5.13 |
| 52-Week Range | 3.22 - 12.30 |
| Beta | 0.88 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva pl...
News
Summit Therapeutics Appoints Prominent Biotech Attorney and Advisor Kenneth A. Clark to Its Board of Directors
Cambridge, MA, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Kenneth A. Clark, JD, has been appointed to our Board of Directors, effective immediately. M...
(SMMT) Alert: Did You Lose Money on Your Summit Therapeutics Investment? Contact Johnson Fistel Regarding Investigation
SAN DIEGO, Oct. 2, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Summit Therapeutics Inc. ("Summit" or the ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Summit Therapeutics Inc. - SMMT
New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investo...
Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investig...
Cambridge, Massachusetts, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying an important ePoster at IDWeek 2021. IDWeek is the jo...
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021
WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today a...
FDA Not In Favor Of Summit Therapeutics' Endpoint Change To Pivotal Infection Trials
Summit Therapeutics Inc (NASDAQ: SMMT) announced that the FDA disagrees with its proposed change to the primary endpoint in Phase 3 Ri-CoDIFy studies. In a regulatory filing, the Company said that the f...
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended Ju...
Cambridge, Massachusetts, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its o...
Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbio...
Data Additionally include Potential Benefit for the Control of Antimicrobial Resistance and a Novel Mechanism of Action Data Additionally include Potential Benefit for the Control of Antimicrobial Resis...
Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Ra...
Cambridge, MA, July 01, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (the “Company”) today announced that members of our scientific team will present breakthrough research updates at...
Summit Therapeutics set to join Russell 3000® Index
Cambridge, MA, June 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconsti...
Summit Therapeutics PLC (SMMT) Moves 17.4% Higher: Will This Strength Last?
Summit Therapeutics PLC (SMMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric...
Summit Therapeutics Stock Surges Higher But Slams Into A Wall Of Resistance
Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) stock had a big move higher Monday. After reporting earnings and giving a clinical trial update, the stock gained $1.44 a share, a move of almost 27%.
Summit Therapeutics Unveils Preclinical Candidate For Multidrug-Resistant Infections
Summit Therapeutics Inc (NASDAQ: SMMT) has selected a new preclinical candidate, SMT026738 (SMT-738), for development against multidrug-resistant infections, specifically carbapenem-resistant Enterobact...
These 2 Nasdaq Stock Winners Could Change the World
Find out why investors are more excited than ever about these two businesses.
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021
Cambridge, MA, May 17, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2021.
Summit Therapeutics Announces Closing of $75 Million Rights Offering
Cambridge, MA, May 12, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today the successful closing of its fully subscribed rights offering and the associated results.
Summit Therapeutics Publishes Scientific Updates to Corporate Website
Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that we have updated the scientific and related content on our corporate website with respect to our investigational ...
Summit Therapeutics' Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscr...
Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight Time ...
Summit Therapeutics Announces Commencement of Rights Offering
Summit Therapeutics Inc. (‘Summit' or the ‘Company')
Summit Therapeutics Announces Rights Offering
Cambridge, MA, March 26, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the Company's Board of Directors has approved a rights offering available to all holders of record of the Com...
Summit Therapeutics (SMMT) Surges: Stock Moves 7.2% Higher
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Summit Therapeutics Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer
Summit Therapeutics Inc. (‘Summit,' the ‘Company,' or the ‘Group')
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended Se...
Summit Therapeutics Inc. (‘Summit', the ‘Company' or the ‘Group')
Summit Announces Closing of Private Placement of $50 Million
Summit Therapeutics Inc. (“Summit” or the “Company”)
Summit Announces Agreement For a Fundraising of approximately $50 Million
Summit Therapeutics Inc.